<?xml version="1.0" encoding="UTF-8"?>
<TED_EXPORT xmlns:xlink="http://www.w3.org/1999/xlink"
            xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
            xmlns="ted/R2.0.9.S02/publication"
            xmlns:n2016="ted/2016/nuts"
            xsi:schemaLocation="ted/R2.0.9.S02/publication TED_EXPORT.xsd"
            VERSION="R2.0.9.S02.E01"
            DOC_ID="183790-2018"
            EDITION="2018082">
   <TECHNICAL_SECTION>
      <RECEPTION_ID>18-186914-001</RECEPTION_ID>
      <DELETION_DATE>20180803</DELETION_DATE>
      <FORM_LG_LIST>PL </FORM_LG_LIST>
      <COMMENTS>From Convertor</COMMENTS>
   </TECHNICAL_SECTION>
   <LINKS_SECTION>
      <XML_SCHEMA_DEFINITION_LINK xlink:type="simple"
                                  xlink:href="http://ted.europa.eu"
                                  xlink:title="TED WEBSITE"/>
      <OFFICIAL_FORMS_LINK xlink:type="simple" xlink:href="http://ted.europa.eu"/>
      <FORMS_LABELS_LINK xlink:type="simple" xlink:href="http://ted.europa.eu"/>
      <ORIGINAL_CPV_LINK xlink:type="simple" xlink:href="http://ted.europa.eu"/>
      <ORIGINAL_NUTS_LINK xlink:type="simple" xlink:href="http://ted.europa.eu"/>
   </LINKS_SECTION>
   <CODED_DATA_SECTION>
      <REF_OJS>
         <COLL_OJ>S</COLL_OJ>
         <NO_OJ>82</NO_OJ>
         <DATE_PUB>20180427</DATE_PUB>
      </REF_OJS>
      <NOTICE_DATA>
         <NO_DOC_OJS>2018/S 082-183790</NO_DOC_OJS>
         <URI_LIST>
            <URI_DOC LG="PL">http://ted.europa.eu/udl?uri=TED:NOTICE:183790-2018:TEXT:PL:HTML</URI_DOC>
         </URI_LIST>
         <LG_ORIG>PL</LG_ORIG>
         <ISO_COUNTRY VALUE="PL"/>
         <IA_URL_GENERAL>www.szpital.kalisz.pl</IA_URL_GENERAL>
         <ORIGINAL_CPV CODE="33600000">Pharmaceutical products</ORIGINAL_CPV>
         <n2016:PERFORMANCE_NUTS CODE="PL416">Kaliski</n2016:PERFORMANCE_NUTS>
         <n2016:CA_CE_NUTS CODE="PL416">Kaliski</n2016:CA_CE_NUTS>
         <n2016:TENDERER_NUTS CODE="PL911">Miasto Warszawa</n2016:TENDERER_NUTS>
         <n2016:TENDERER_NUTS CODE="PL514">Miasto Wrocław</n2016:TENDERER_NUTS>
         <n2016:TENDERER_NUTS CODE="PL711">Miasto Łódź</n2016:TENDERER_NUTS>
         <n2016:TENDERER_NUTS CODE="PL22A">Katowicki</n2016:TENDERER_NUTS>
         <VALUES>
            <VALUE TYPE="PROCUREMENT_TOTAL" CURRENCY="PLN">11238112.40</VALUE>
         </VALUES>
         <REF_NOTICE>
            <NO_DOC_OJS>2018/S 021-043551</NO_DOC_OJS>
         </REF_NOTICE>
      </NOTICE_DATA>
      <CODIF_DATA>
         <DS_DATE_DISPATCH>20180425</DS_DATE_DISPATCH>
         <AA_AUTHORITY_TYPE CODE="6">Body governed by public law</AA_AUTHORITY_TYPE>
         <TD_DOCUMENT_TYPE CODE="7">Contract award notice</TD_DOCUMENT_TYPE>
         <NC_CONTRACT_NATURE CODE="2">Supplies</NC_CONTRACT_NATURE>
         <PR_PROC CODE="B">Competitive procedure with negotiation</PR_PROC>
         <RP_REGULATION CODE="5">European Union, with participation by GPA countries</RP_REGULATION>
         <TY_TYPE_BID CODE="9">Not applicable</TY_TYPE_BID>
         <AC_AWARD_CRIT CODE="1">Lowest price</AC_AWARD_CRIT>
         <MA_MAIN_ACTIVITIES CODE="H">Health</MA_MAIN_ACTIVITIES>
         <HEADING>01B03</HEADING>
         <INITIATOR>01</INITIATOR>
         <DIRECTIVE VALUE="2014/24/EU"/>
      </CODIF_DATA>
   </CODED_DATA_SECTION>
   <TRANSLATION_SECTION>
      <ML_TITLES>
         <ML_TI_DOC LG="BG">
            <TI_CY>Полша</TI_CY>
            <TI_TOWN>Kalisz</TI_TOWN>
            <TI_TEXT>
               <P>Фармацевтични продукти</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="CS">
            <TI_CY>Polsko</TI_CY>
            <TI_TOWN>Kalisz</TI_TOWN>
            <TI_TEXT>
               <P>Léčivé přípravky a zdravotnické prostředky</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="DA">
            <TI_CY>Polen</TI_CY>
            <TI_TOWN>Kalisz</TI_TOWN>
            <TI_TEXT>
               <P>Lægemidler</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="DE">
            <TI_CY>Polen</TI_CY>
            <TI_TOWN>Kalisz</TI_TOWN>
            <TI_TEXT>
               <P>Arzneimittel</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="EL">
            <TI_CY>Πολωνία</TI_CY>
            <TI_TOWN>Kalisz</TI_TOWN>
            <TI_TEXT>
               <P>Φαρμακευτικά προϊόντα</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="EN">
            <TI_CY>Poland</TI_CY>
            <TI_TOWN>Kalisz</TI_TOWN>
            <TI_TEXT>
               <P>Pharmaceutical products</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="ES">
            <TI_CY>Polonia</TI_CY>
            <TI_TOWN>Kalisz</TI_TOWN>
            <TI_TEXT>
               <P>Productos farmacéuticos</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="ET">
            <TI_CY>Poola</TI_CY>
            <TI_TOWN>Kalisz</TI_TOWN>
            <TI_TEXT>
               <P>Ravimid</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="FI">
            <TI_CY>Puola</TI_CY>
            <TI_TOWN>Kalisz</TI_TOWN>
            <TI_TEXT>
               <P>Farmaseuttiset tuotteet</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="FR">
            <TI_CY>Pologne</TI_CY>
            <TI_TOWN>Kalisz</TI_TOWN>
            <TI_TEXT>
               <P>Produits pharmaceutiques</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="GA">
            <TI_CY>Pholainn, an</TI_CY>
            <TI_TOWN>Kalisz</TI_TOWN>
            <TI_TEXT>
               <P>Pharmaceutical products</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="HR">
            <TI_CY>Poljska</TI_CY>
            <TI_TOWN>Kalisz</TI_TOWN>
            <TI_TEXT>
               <P>Farmaceutski proizvodi</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="HU">
            <TI_CY>Lengyelország</TI_CY>
            <TI_TOWN>Kalisz</TI_TOWN>
            <TI_TEXT>
               <P>Gyógyszerészeti termékek</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="IT">
            <TI_CY>Polonia</TI_CY>
            <TI_TOWN>Kalisz</TI_TOWN>
            <TI_TEXT>
               <P>Prodotti farmaceutici</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="LT">
            <TI_CY>Lenkija</TI_CY>
            <TI_TOWN>Kalisz</TI_TOWN>
            <TI_TEXT>
               <P>Farmacijos produktai</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="LV">
            <TI_CY>Polija</TI_CY>
            <TI_TOWN>Kalisz</TI_TOWN>
            <TI_TEXT>
               <P>Farmācijas izstrādājumi</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="MT">
            <TI_CY>il-Polonja</TI_CY>
            <TI_TOWN>Kalisz</TI_TOWN>
            <TI_TEXT>
               <P>Prodotti farmaċewtiċi</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="NL">
            <TI_CY>Polen</TI_CY>
            <TI_TOWN>Kalisz</TI_TOWN>
            <TI_TEXT>
               <P>Farmaceutische producten</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="PL">
            <TI_CY>Polska</TI_CY>
            <TI_TOWN>Kalisz</TI_TOWN>
            <TI_TEXT>
               <P>Produkty farmaceutyczne</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="PT">
            <TI_CY>Polónia</TI_CY>
            <TI_TOWN>Kalisz</TI_TOWN>
            <TI_TEXT>
               <P>Produtos farmacêuticos</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="RO">
            <TI_CY>Polonia</TI_CY>
            <TI_TOWN>Kalisz</TI_TOWN>
            <TI_TEXT>
               <P>Produse farmaceutice</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="SK">
            <TI_CY>Poľsko</TI_CY>
            <TI_TOWN>Kalisz</TI_TOWN>
            <TI_TEXT>
               <P>Farmaceutické výrobky</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="SL">
            <TI_CY>Poljska</TI_CY>
            <TI_TOWN>Kalisz</TI_TOWN>
            <TI_TEXT>
               <P>Farmacevtski proizvodi</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="SV">
            <TI_CY>Polen</TI_CY>
            <TI_TOWN>Kalisz</TI_TOWN>
            <TI_TEXT>
               <P>Läkemedel</P>
            </TI_TEXT>
         </ML_TI_DOC>
      </ML_TITLES>
      <ML_AA_NAMES>
         <AA_NAME LG="PL">Wojewódzki Szpital Zespolony im. L. Perzyny w Kaliszu</AA_NAME>
      </ML_AA_NAMES>
   </TRANSLATION_SECTION>
   <FORM_SECTION>
      <F03_2014 CATEGORY="ORIGINAL" FORM="F03" LG="PL">
         <CONTRACTING_BODY>
            <ADDRESS_CONTRACTING_BODY>
               <OFFICIALNAME>Wojewódzki Szpital Zespolony im. L. Perzyny w Kaliszu</OFFICIALNAME>
               <ADDRESS>ul. Poznańska 79</ADDRESS>
               <TOWN>Kalisz</TOWN>
               <POSTAL_CODE>62-800</POSTAL_CODE>
               <COUNTRY VALUE="PL"/>
               <PHONE>+48 627651397</PHONE>
               <E_MAIL>zam.pub_szpital.kalisz@poczta.fm</E_MAIL>
               <FAX>+48 627571323</FAX>
               <n2016:NUTS CODE="PL416"/>
               <URL_GENERAL>www.szpital.kalisz.pl</URL_GENERAL>
            </ADDRESS_CONTRACTING_BODY>
            <CA_TYPE VALUE="BODY_PUBLIC"/>
            <CA_ACTIVITY VALUE="HEALTH"/>
         </CONTRACTING_BODY>
         <OBJECT_CONTRACT>
            <TITLE>
               <P>Sukcesywne dostawy produktów farmaceutycznych</P>
            </TITLE>
            <REFERENCE_NUMBER>05/18</REFERENCE_NUMBER>
            <CPV_MAIN>
               <CPV_CODE CODE="33600000"/>
            </CPV_MAIN>
            <TYPE_CONTRACT CTYPE="SUPPLIES"/>
            <SHORT_DESCR>
               <P>Sukcesywne dostawy produktów farmaceutycznych. Przedmiot zamówienia składa się z 18 niepodzielnych zadań, których szczegółowy opis znajduje się w Specyfikacji Istotnych Warunków Zamówienia.</P>
            </SHORT_DESCR>
            <VAL_TOTAL CURRENCY="PLN">11238112.40</VAL_TOTAL>
            <LOT_DIVISION/>
            <OBJECT_DESCR ITEM="1">
               <TITLE>
                  <P>Leki stosowane w terapii bezinterferonowej WZW typu C</P>
               </TITLE>
               <LOT_NO>1</LOT_NO>
               <CPV_ADDITIONAL>
                  <CPV_CODE CODE="33600000"/>
               </CPV_ADDITIONAL>
               <n2016:NUTS CODE="PL416"/>
               <MAIN_SITE>
                  <P>Siedziba Zamawiającego.</P>
               </MAIN_SITE>
               <SHORT_DESCR>
                  <P>Leki stosowane w terapii bezinterferonowej WZW typu C.</P>
               </SHORT_DESCR>
               <AC_PRICE/>
               <NO_OPTIONS/>
               <NO_EU_PROGR_RELATED/>
            </OBJECT_DESCR>
            <OBJECT_DESCR ITEM="2">
               <TITLE>
                  <P>Ledipasvir. Sofosbuvir</P>
               </TITLE>
               <LOT_NO>2</LOT_NO>
               <CPV_ADDITIONAL>
                  <CPV_CODE CODE="33600000"/>
               </CPV_ADDITIONAL>
               <n2016:NUTS CODE="PL416"/>
               <MAIN_SITE>
                  <P>Siedziba Zamawiającego.</P>
               </MAIN_SITE>
               <SHORT_DESCR>
                  <P>Ledipasvir. Sofosbuvir.</P>
               </SHORT_DESCR>
               <AC_PRICE/>
               <NO_OPTIONS/>
               <NO_EU_PROGR_RELATED/>
            </OBJECT_DESCR>
            <OBJECT_DESCR ITEM="3">
               <TITLE>
                  <P>Sofosbuvir</P>
               </TITLE>
               <LOT_NO>3</LOT_NO>
               <CPV_ADDITIONAL>
                  <CPV_CODE CODE="33600000"/>
               </CPV_ADDITIONAL>
               <n2016:NUTS CODE="PL416"/>
               <MAIN_SITE>
                  <P>Siedziba Zamawiającego.</P>
               </MAIN_SITE>
               <SHORT_DESCR>
                  <P>Sofosbuvir.</P>
               </SHORT_DESCR>
               <AC_PRICE/>
               <NO_OPTIONS/>
               <NO_EU_PROGR_RELATED/>
            </OBJECT_DESCR>
            <OBJECT_DESCR ITEM="4">
               <TITLE>
                  <P>Elbasvir. Grazoprevir</P>
               </TITLE>
               <LOT_NO>4</LOT_NO>
               <CPV_ADDITIONAL>
                  <CPV_CODE CODE="33600000"/>
               </CPV_ADDITIONAL>
               <n2016:NUTS CODE="PL416"/>
               <MAIN_SITE>
                  <P>Siedziba Zamawiającego.</P>
               </MAIN_SITE>
               <SHORT_DESCR>
                  <P>Elbasvir. Grazoprevir.</P>
               </SHORT_DESCR>
               <AC_PRICE/>
               <NO_OPTIONS/>
               <NO_EU_PROGR_RELATED/>
            </OBJECT_DESCR>
            <OBJECT_DESCR ITEM="5">
               <TITLE>
                  <P>Abiraterone</P>
               </TITLE>
               <LOT_NO>5</LOT_NO>
               <CPV_ADDITIONAL>
                  <CPV_CODE CODE="33600000"/>
               </CPV_ADDITIONAL>
               <n2016:NUTS CODE="PL416"/>
               <MAIN_SITE>
                  <P>Siedziba Zamawiającego.</P>
               </MAIN_SITE>
               <SHORT_DESCR>
                  <P>Abiraterone.</P>
               </SHORT_DESCR>
               <AC_PRICE/>
               <NO_OPTIONS/>
               <NO_EU_PROGR_RELATED/>
            </OBJECT_DESCR>
            <OBJECT_DESCR ITEM="6">
               <TITLE>
                  <P>Aflibercept</P>
               </TITLE>
               <LOT_NO>6</LOT_NO>
               <CPV_ADDITIONAL>
                  <CPV_CODE CODE="33600000"/>
               </CPV_ADDITIONAL>
               <n2016:NUTS CODE="PL416"/>
               <MAIN_SITE>
                  <P>Siedziba Zamawiającego.</P>
               </MAIN_SITE>
               <SHORT_DESCR>
                  <P>Aflibercept.</P>
               </SHORT_DESCR>
               <AC_PRICE/>
               <NO_OPTIONS/>
               <NO_EU_PROGR_RELATED/>
            </OBJECT_DESCR>
            <OBJECT_DESCR ITEM="7">
               <TITLE>
                  <P>Axitinib</P>
               </TITLE>
               <LOT_NO>7</LOT_NO>
               <CPV_ADDITIONAL>
                  <CPV_CODE CODE="33600000"/>
               </CPV_ADDITIONAL>
               <n2016:NUTS CODE="PL416"/>
               <MAIN_SITE>
                  <P>Siedziba Zamawiającego.</P>
               </MAIN_SITE>
               <SHORT_DESCR>
                  <P>Axitinib.</P>
               </SHORT_DESCR>
               <AC_PRICE/>
               <NO_OPTIONS/>
               <NO_EU_PROGR_RELATED/>
            </OBJECT_DESCR>
            <OBJECT_DESCR ITEM="8">
               <TITLE>
                  <P>Doxorubicin hydrochloride</P>
               </TITLE>
               <LOT_NO>8</LOT_NO>
               <CPV_ADDITIONAL>
                  <CPV_CODE CODE="33600000"/>
               </CPV_ADDITIONAL>
               <n2016:NUTS CODE="PL416"/>
               <MAIN_SITE>
                  <P>Siedziba Zamawiającego.</P>
               </MAIN_SITE>
               <SHORT_DESCR>
                  <P>Doxorubicin hydrochloride.</P>
               </SHORT_DESCR>
               <AC_PRICE/>
               <NO_OPTIONS/>
               <NO_EU_PROGR_RELATED/>
            </OBJECT_DESCR>
            <OBJECT_DESCR ITEM="9">
               <TITLE>
                  <P>Everolimus</P>
               </TITLE>
               <LOT_NO>9</LOT_NO>
               <CPV_ADDITIONAL>
                  <CPV_CODE CODE="33600000"/>
               </CPV_ADDITIONAL>
               <n2016:NUTS CODE="PL416"/>
               <MAIN_SITE>
                  <P>Siedziba Zamawiającego.</P>
               </MAIN_SITE>
               <SHORT_DESCR>
                  <P>Everolimus.</P>
               </SHORT_DESCR>
               <AC_PRICE/>
               <NO_OPTIONS/>
               <NO_EU_PROGR_RELATED/>
            </OBJECT_DESCR>
            <OBJECT_DESCR ITEM="10">
               <TITLE>
                  <P>Paclitaxel</P>
               </TITLE>
               <LOT_NO>10</LOT_NO>
               <CPV_ADDITIONAL>
                  <CPV_CODE CODE="33600000"/>
               </CPV_ADDITIONAL>
               <n2016:NUTS CODE="PL416"/>
               <MAIN_SITE>
                  <P>Siedziba Zamawiającego.</P>
               </MAIN_SITE>
               <SHORT_DESCR>
                  <P>Paclitaxel.</P>
               </SHORT_DESCR>
               <AC_PRICE/>
               <NO_OPTIONS/>
               <NO_EU_PROGR_RELATED/>
            </OBJECT_DESCR>
            <OBJECT_DESCR ITEM="11">
               <TITLE>
                  <P>Pazopanib</P>
               </TITLE>
               <LOT_NO>11</LOT_NO>
               <CPV_ADDITIONAL>
                  <CPV_CODE CODE="33600000"/>
               </CPV_ADDITIONAL>
               <n2016:NUTS CODE="PL416"/>
               <MAIN_SITE>
                  <P>Siedziba Zamawiającego.</P>
               </MAIN_SITE>
               <SHORT_DESCR>
                  <P>Pazopanib.</P>
               </SHORT_DESCR>
               <AC_PRICE/>
               <NO_OPTIONS/>
               <NO_EU_PROGR_RELATED/>
            </OBJECT_DESCR>
            <OBJECT_DESCR ITEM="12">
               <TITLE>
                  <P>Sorafenib</P>
               </TITLE>
               <LOT_NO>12</LOT_NO>
               <CPV_ADDITIONAL>
                  <CPV_CODE CODE="33600000"/>
               </CPV_ADDITIONAL>
               <n2016:NUTS CODE="PL416"/>
               <MAIN_SITE>
                  <P>Siedziba Zamawiającego.</P>
               </MAIN_SITE>
               <SHORT_DESCR>
                  <P>Sorafenib.</P>
               </SHORT_DESCR>
               <AC_PRICE/>
               <NO_OPTIONS/>
               <NO_EU_PROGR_RELATED/>
            </OBJECT_DESCR>
            <OBJECT_DESCR ITEM="13">
               <TITLE>
                  <P>Sunitinib</P>
               </TITLE>
               <LOT_NO>13</LOT_NO>
               <CPV_ADDITIONAL>
                  <CPV_CODE CODE="33600000"/>
               </CPV_ADDITIONAL>
               <n2016:NUTS CODE="PL416"/>
               <MAIN_SITE>
                  <P>Siedziba Zamawiającego.</P>
               </MAIN_SITE>
               <SHORT_DESCR>
                  <P>Sunitinib.</P>
               </SHORT_DESCR>
               <AC_PRICE/>
               <NO_OPTIONS/>
               <NO_EU_PROGR_RELATED/>
            </OBJECT_DESCR>
            <OBJECT_DESCR ITEM="14">
               <TITLE>
                  <P>Temsirolimus</P>
               </TITLE>
               <LOT_NO>14</LOT_NO>
               <CPV_ADDITIONAL>
                  <CPV_CODE CODE="33600000"/>
               </CPV_ADDITIONAL>
               <n2016:NUTS CODE="PL416"/>
               <MAIN_SITE>
                  <P>Siedziba Zamawiającego.</P>
               </MAIN_SITE>
               <SHORT_DESCR>
                  <P>Temsirolimus.</P>
               </SHORT_DESCR>
               <AC_PRICE/>
               <NO_OPTIONS/>
               <NO_EU_PROGR_RELATED/>
            </OBJECT_DESCR>
            <OBJECT_DESCR ITEM="15">
               <TITLE>
                  <P>Trastuzumab</P>
               </TITLE>
               <LOT_NO>15</LOT_NO>
               <CPV_ADDITIONAL>
                  <CPV_CODE CODE="33600000"/>
               </CPV_ADDITIONAL>
               <n2016:NUTS CODE="PL416"/>
               <MAIN_SITE>
                  <P>Siedziba Zamawiającego.</P>
               </MAIN_SITE>
               <SHORT_DESCR>
                  <P>Trastuzumab.</P>
               </SHORT_DESCR>
               <AC_PRICE/>
               <NO_OPTIONS/>
               <NO_EU_PROGR_RELATED/>
            </OBJECT_DESCR>
            <OBJECT_DESCR ITEM="16">
               <TITLE>
                  <P>Bleomycin sulphate</P>
               </TITLE>
               <LOT_NO>16</LOT_NO>
               <CPV_ADDITIONAL>
                  <CPV_CODE CODE="33600000"/>
               </CPV_ADDITIONAL>
               <n2016:NUTS CODE="PL416"/>
               <MAIN_SITE>
                  <P>Siedziba Zamawiającego.</P>
               </MAIN_SITE>
               <SHORT_DESCR>
                  <P>Bleomycin sulphate.</P>
               </SHORT_DESCR>
               <AC_PRICE/>
               <NO_OPTIONS/>
               <NO_EU_PROGR_RELATED/>
            </OBJECT_DESCR>
            <OBJECT_DESCR ITEM="17">
               <TITLE>
                  <P>Carbolatinum</P>
               </TITLE>
               <LOT_NO>17</LOT_NO>
               <CPV_ADDITIONAL>
                  <CPV_CODE CODE="33600000"/>
               </CPV_ADDITIONAL>
               <n2016:NUTS CODE="PL416"/>
               <MAIN_SITE>
                  <P>Siedziba Zamawiającego.</P>
               </MAIN_SITE>
               <SHORT_DESCR>
                  <P>Carbolatinum.</P>
               </SHORT_DESCR>
               <AC_PRICE/>
               <NO_OPTIONS/>
               <NO_EU_PROGR_RELATED/>
            </OBJECT_DESCR>
            <OBJECT_DESCR ITEM="18">
               <TITLE>
                  <P>Enzalutamide</P>
               </TITLE>
               <LOT_NO>18</LOT_NO>
               <CPV_ADDITIONAL>
                  <CPV_CODE CODE="33600000"/>
               </CPV_ADDITIONAL>
               <n2016:NUTS CODE="PL416"/>
               <MAIN_SITE>
                  <P>Siedziba Zamawiającego.</P>
               </MAIN_SITE>
               <SHORT_DESCR>
                  <P>Enzalutamide.</P>
               </SHORT_DESCR>
               <AC_PRICE/>
               <NO_OPTIONS/>
               <NO_EU_PROGR_RELATED/>
            </OBJECT_DESCR>
         </OBJECT_CONTRACT>
         <PROCEDURE>
            <PT_COMPETITIVE_NEGOTIATION/>
            <CONTRACT_COVERED_GPA/>
            <NOTICE_NUMBER_OJ>2018/S 021-043551</NOTICE_NUMBER_OJ>
         </PROCEDURE>
         <AWARD_CONTRACT ITEM="1">
            <CONTRACT_NO>1</CONTRACT_NO>
            <LOT_NO>1</LOT_NO>
            <TITLE>
               <P>Leki stosowane w terapii bezinterferonowej WZW typu C</P>
            </TITLE>
            <AWARDED_CONTRACT>
               <DATE_CONCLUSION_CONTRACT>2018-03-27</DATE_CONCLUSION_CONTRACT>
               <NB_TENDERS_RECEIVED>1</NB_TENDERS_RECEIVED>
               <NO_AWARDED_TO_GROUP/>
               <CONTRACTOR>
                  <ADDRESS_CONTRACTOR>
                     <OFFICIALNAME>AbbVie Sp. z o.o.</OFFICIALNAME>
                     <TOWN>Warszawa</TOWN>
                     <COUNTRY VALUE="PL"/>
                     <n2016:NUTS CODE="PL911"/>
                  </ADDRESS_CONTRACTOR>
                  <NO_SME/>
               </CONTRACTOR>
               <VAL_ESTIMATED_TOTAL CURRENCY="PLN">2407456.00</VAL_ESTIMATED_TOTAL>
               <VAL_TOTAL CURRENCY="PLN">2600052.48</VAL_TOTAL>
            </AWARDED_CONTRACT>
         </AWARD_CONTRACT>
         <AWARD_CONTRACT ITEM="2">
            <CONTRACT_NO>2</CONTRACT_NO>
            <LOT_NO>2</LOT_NO>
            <TITLE>
               <P>Ledipasvir. Sofosbuvir</P>
            </TITLE>
            <AWARDED_CONTRACT>
               <DATE_CONCLUSION_CONTRACT>2018-03-27</DATE_CONCLUSION_CONTRACT>
               <NB_TENDERS_RECEIVED>1</NB_TENDERS_RECEIVED>
               <AWARDED_TO_GROUP/>
               <CONTRACTOR>
                  <ADDRESS_CONTRACTOR>
                     <OFFICIALNAME>PGF „Urtica” Sp. z o.o.</OFFICIALNAME>
                     <TOWN>Wrocław</TOWN>
                     <COUNTRY VALUE="PL"/>
                     <n2016:NUTS CODE="PL514"/>
                  </ADDRESS_CONTRACTOR>
                  <NO_SME/>
               </CONTRACTOR>
               <CONTRACTOR>
                  <ADDRESS_CONTRACTOR>
                     <OFFICIALNAME>Polska Grupa Farmaceutyczna S.A.</OFFICIALNAME>
                     <TOWN>Łódź</TOWN>
                     <COUNTRY VALUE="PL"/>
                     <n2016:NUTS CODE="PL711"/>
                  </ADDRESS_CONTRACTOR>
                  <NO_SME/>
               </CONTRACTOR>
               <VAL_ESTIMATED_TOTAL CURRENCY="PLN">6825000.00</VAL_ESTIMATED_TOTAL>
               <VAL_TOTAL CURRENCY="PLN">7371000.00</VAL_TOTAL>
            </AWARDED_CONTRACT>
         </AWARD_CONTRACT>
         <AWARD_CONTRACT ITEM="3">
            <CONTRACT_NO>3</CONTRACT_NO>
            <LOT_NO>3</LOT_NO>
            <TITLE>
               <P>Sofosbuvir</P>
            </TITLE>
            <AWARDED_CONTRACT>
               <DATE_CONCLUSION_CONTRACT>2018-03-27</DATE_CONCLUSION_CONTRACT>
               <NB_TENDERS_RECEIVED>1</NB_TENDERS_RECEIVED>
               <AWARDED_TO_GROUP/>
               <CONTRACTOR>
                  <ADDRESS_CONTRACTOR>
                     <OFFICIALNAME>PGF „Urtica” Sp. z o.o.</OFFICIALNAME>
                     <TOWN>Wrocław</TOWN>
                     <COUNTRY VALUE="PL"/>
                     <n2016:NUTS CODE="PL514"/>
                  </ADDRESS_CONTRACTOR>
                  <NO_SME/>
               </CONTRACTOR>
               <CONTRACTOR>
                  <ADDRESS_CONTRACTOR>
                     <OFFICIALNAME>Polska Grupa Farmaceutyczna S.A.</OFFICIALNAME>
                     <TOWN>Łódź</TOWN>
                     <COUNTRY VALUE="PL"/>
                     <n2016:NUTS CODE="PL711"/>
                  </ADDRESS_CONTRACTOR>
                  <NO_SME/>
               </CONTRACTOR>
               <VAL_ESTIMATED_TOTAL CURRENCY="PLN">1461600.00</VAL_ESTIMATED_TOTAL>
               <VAL_TOTAL CURRENCY="PLN">1578528.00</VAL_TOTAL>
            </AWARDED_CONTRACT>
         </AWARD_CONTRACT>
         <AWARD_CONTRACT ITEM="4">
            <CONTRACT_NO>4</CONTRACT_NO>
            <LOT_NO>4</LOT_NO>
            <TITLE>
               <P>Elbasvir. Grazoprevir</P>
            </TITLE>
            <AWARDED_CONTRACT>
               <DATE_CONCLUSION_CONTRACT>2018-03-27</DATE_CONCLUSION_CONTRACT>
               <NB_TENDERS_RECEIVED>1</NB_TENDERS_RECEIVED>
               <AWARDED_TO_GROUP/>
               <CONTRACTOR>
                  <ADDRESS_CONTRACTOR>
                     <OFFICIALNAME>PGF „Urtica” Sp. z o.o.</OFFICIALNAME>
                     <TOWN>Wrocław</TOWN>
                     <COUNTRY VALUE="PL"/>
                     <n2016:NUTS CODE="PL514"/>
                  </ADDRESS_CONTRACTOR>
                  <NO_SME/>
               </CONTRACTOR>
               <CONTRACTOR>
                  <ADDRESS_CONTRACTOR>
                     <OFFICIALNAME>Polska Grupa Farmaceutyczna S.A.</OFFICIALNAME>
                     <TOWN>Łódź</TOWN>
                     <COUNTRY VALUE="PL"/>
                     <n2016:NUTS CODE="PL711"/>
                  </ADDRESS_CONTRACTOR>
                  <NO_SME/>
               </CONTRACTOR>
               <VAL_ESTIMATED_TOTAL CURRENCY="PLN">86666.64</VAL_ESTIMATED_TOTAL>
               <VAL_TOTAL CURRENCY="PLN">93599.97</VAL_TOTAL>
            </AWARDED_CONTRACT>
         </AWARD_CONTRACT>
         <AWARD_CONTRACT ITEM="5">
            <CONTRACT_NO>5</CONTRACT_NO>
            <LOT_NO>5</LOT_NO>
            <TITLE>
               <P>Abiraterone</P>
            </TITLE>
            <AWARDED_CONTRACT>
               <DATE_CONCLUSION_CONTRACT>2018-03-27</DATE_CONCLUSION_CONTRACT>
               <NB_TENDERS_RECEIVED>1</NB_TENDERS_RECEIVED>
               <NB_TENDERS_RECEIVED_SME>1</NB_TENDERS_RECEIVED_SME>
               <NO_AWARDED_TO_GROUP/>
               <CONTRACTOR>
                  <ADDRESS_CONTRACTOR>
                     <OFFICIALNAME>Janssen – Cilag Polska Sp. z o.o.</OFFICIALNAME>
                     <TOWN>Warszawa</TOWN>
                     <COUNTRY VALUE="PL"/>
                     <n2016:NUTS CODE="PL911"/>
                  </ADDRESS_CONTRACTOR>
                  <SME/>
               </CONTRACTOR>
               <VAL_ESTIMATED_TOTAL CURRENCY="PLN">33385.00</VAL_ESTIMATED_TOTAL>
               <VAL_TOTAL CURRENCY="PLN">34260.68</VAL_TOTAL>
            </AWARDED_CONTRACT>
         </AWARD_CONTRACT>
         <AWARD_CONTRACT ITEM="6">
            <CONTRACT_NO>6</CONTRACT_NO>
            <LOT_NO>6</LOT_NO>
            <TITLE>
               <P>Aflibercept</P>
            </TITLE>
            <AWARDED_CONTRACT>
               <DATE_CONCLUSION_CONTRACT>2018-03-27</DATE_CONCLUSION_CONTRACT>
               <NB_TENDERS_RECEIVED>1</NB_TENDERS_RECEIVED>
               <NO_AWARDED_TO_GROUP/>
               <CONTRACTOR>
                  <ADDRESS_CONTRACTOR>
                     <OFFICIALNAME>Sanofi – Aventis Sp. z o.o.</OFFICIALNAME>
                     <TOWN>Warszawa</TOWN>
                     <COUNTRY VALUE="PL"/>
                     <n2016:NUTS CODE="PL911"/>
                  </ADDRESS_CONTRACTOR>
                  <NO_SME/>
               </CONTRACTOR>
               <VAL_ESTIMATED_TOTAL CURRENCY="PLN">17010.00</VAL_ESTIMATED_TOTAL>
               <VAL_TOTAL CURRENCY="PLN">15999.98</VAL_TOTAL>
            </AWARDED_CONTRACT>
         </AWARD_CONTRACT>
         <AWARD_CONTRACT ITEM="7">
            <CONTRACT_NO>7</CONTRACT_NO>
            <LOT_NO>7</LOT_NO>
            <TITLE>
               <P>Axitinib</P>
            </TITLE>
            <AWARDED_CONTRACT>
               <DATE_CONCLUSION_CONTRACT>2018-03-27</DATE_CONCLUSION_CONTRACT>
               <NB_TENDERS_RECEIVED>1</NB_TENDERS_RECEIVED>
               <NO_AWARDED_TO_GROUP/>
               <CONTRACTOR>
                  <ADDRESS_CONTRACTOR>
                     <OFFICIALNAME>Pfizer Trading Polska Sp. z o.o.</OFFICIALNAME>
                     <TOWN>Warszawa</TOWN>
                     <COUNTRY VALUE="PL"/>
                     <n2016:NUTS CODE="PL911"/>
                  </ADDRESS_CONTRACTOR>
                  <NO_SME/>
               </CONTRACTOR>
               <VAL_ESTIMATED_TOTAL CURRENCY="PLN">32578.00</VAL_ESTIMATED_TOTAL>
               <VAL_TOTAL CURRENCY="PLN">18205.29</VAL_TOTAL>
            </AWARDED_CONTRACT>
         </AWARD_CONTRACT>
         <AWARD_CONTRACT ITEM="8">
            <CONTRACT_NO>8</CONTRACT_NO>
            <LOT_NO>8</LOT_NO>
            <TITLE>
               <P>Doxorubicin hydrochloride</P>
            </TITLE>
            <AWARDED_CONTRACT>
               <DATE_CONCLUSION_CONTRACT>2018-04-04</DATE_CONCLUSION_CONTRACT>
               <NB_TENDERS_RECEIVED>4</NB_TENDERS_RECEIVED>
               <NB_TENDERS_RECEIVED_SME>1</NB_TENDERS_RECEIVED_SME>
               <NO_AWARDED_TO_GROUP/>
               <CONTRACTOR>
                  <ADDRESS_CONTRACTOR>
                     <OFFICIALNAME>Salus International Sp. z o.o.</OFFICIALNAME>
                     <TOWN>Katowice</TOWN>
                     <COUNTRY VALUE="PL"/>
                     <n2016:NUTS CODE="PL22A"/>
                  </ADDRESS_CONTRACTOR>
                  <NO_SME/>
               </CONTRACTOR>
               <VAL_ESTIMATED_TOTAL CURRENCY="PLN">39375.00</VAL_ESTIMATED_TOTAL>
               <VAL_TOTAL CURRENCY="PLN">40844.30</VAL_TOTAL>
            </AWARDED_CONTRACT>
         </AWARD_CONTRACT>
         <AWARD_CONTRACT ITEM="9">
            <CONTRACT_NO>9</CONTRACT_NO>
            <LOT_NO>9</LOT_NO>
            <TITLE>
               <P>Everolimus</P>
            </TITLE>
            <AWARDED_CONTRACT>
               <DATE_CONCLUSION_CONTRACT>2018-03-27</DATE_CONCLUSION_CONTRACT>
               <NB_TENDERS_RECEIVED>1</NB_TENDERS_RECEIVED>
               <AWARDED_TO_GROUP/>
               <CONTRACTOR>
                  <ADDRESS_CONTRACTOR>
                     <OFFICIALNAME>PGF „Urtica” Sp. z o.o.</OFFICIALNAME>
                     <TOWN>Wrocław</TOWN>
                     <COUNTRY VALUE="PL"/>
                     <n2016:NUTS CODE="PL514"/>
                  </ADDRESS_CONTRACTOR>
                  <NO_SME/>
               </CONTRACTOR>
               <CONTRACTOR>
                  <ADDRESS_CONTRACTOR>
                     <OFFICIALNAME>Polska Grupa Farmaceutyczna S.A.</OFFICIALNAME>
                     <TOWN>Łódź</TOWN>
                     <COUNTRY VALUE="PL"/>
                     <n2016:NUTS CODE="PL711"/>
                  </ADDRESS_CONTRACTOR>
                  <NO_SME/>
               </CONTRACTOR>
               <VAL_ESTIMATED_TOTAL CURRENCY="PLN">42351.00</VAL_ESTIMATED_TOTAL>
               <VAL_TOTAL CURRENCY="PLN">25356.24</VAL_TOTAL>
            </AWARDED_CONTRACT>
         </AWARD_CONTRACT>
         <AWARD_CONTRACT ITEM="10">
            <CONTRACT_NO>10</CONTRACT_NO>
            <LOT_NO>10</LOT_NO>
            <TITLE>
               <P>Paclitaxel</P>
            </TITLE>
            <AWARDED_CONTRACT>
               <DATE_CONCLUSION_CONTRACT>2018-04-04</DATE_CONCLUSION_CONTRACT>
               <NB_TENDERS_RECEIVED>2</NB_TENDERS_RECEIVED>
               <NO_AWARDED_TO_GROUP/>
               <CONTRACTOR>
                  <ADDRESS_CONTRACTOR>
                     <OFFICIALNAME>Komtur Polska Sp. z o.o.</OFFICIALNAME>
                     <TOWN>Warszawa</TOWN>
                     <COUNTRY VALUE="PL"/>
                     <n2016:NUTS CODE="PL911"/>
                  </ADDRESS_CONTRACTOR>
                  <NO_SME/>
               </CONTRACTOR>
               <VAL_ESTIMATED_TOTAL CURRENCY="PLN">37740.50</VAL_ESTIMATED_TOTAL>
               <VAL_TOTAL CURRENCY="PLN">55296.00</VAL_TOTAL>
            </AWARDED_CONTRACT>
         </AWARD_CONTRACT>
         <AWARD_CONTRACT ITEM="11">
            <CONTRACT_NO>11</CONTRACT_NO>
            <LOT_NO>11</LOT_NO>
            <TITLE>
               <P>Pazopanib</P>
            </TITLE>
            <AWARDED_CONTRACT>
               <DATE_CONCLUSION_CONTRACT>2018-03-27</DATE_CONCLUSION_CONTRACT>
               <NB_TENDERS_RECEIVED>1</NB_TENDERS_RECEIVED>
               <AWARDED_TO_GROUP/>
               <CONTRACTOR>
                  <ADDRESS_CONTRACTOR>
                     <OFFICIALNAME>PGF „Urtica” Sp. z o.o.</OFFICIALNAME>
                     <TOWN>Wrocław</TOWN>
                     <COUNTRY VALUE="PL"/>
                     <n2016:NUTS CODE="PL911"/>
                  </ADDRESS_CONTRACTOR>
                  <NO_SME/>
               </CONTRACTOR>
               <CONTRACTOR>
                  <ADDRESS_CONTRACTOR>
                     <OFFICIALNAME>Polska Grupa Farmaceutyczna S.A.</OFFICIALNAME>
                     <TOWN>Łódź</TOWN>
                     <COUNTRY VALUE="PL"/>
                     <n2016:NUTS CODE="PL711"/>
                  </ADDRESS_CONTRACTOR>
                  <NO_SME/>
               </CONTRACTOR>
               <VAL_ESTIMATED_TOTAL CURRENCY="PLN">37554.00</VAL_ESTIMATED_TOTAL>
               <VAL_TOTAL CURRENCY="PLN">24477.37</VAL_TOTAL>
            </AWARDED_CONTRACT>
         </AWARD_CONTRACT>
         <AWARD_CONTRACT ITEM="12">
            <CONTRACT_NO>12</CONTRACT_NO>
            <LOT_NO>12</LOT_NO>
            <TITLE>
               <P>Sorafenib</P>
            </TITLE>
            <AWARDED_CONTRACT>
               <DATE_CONCLUSION_CONTRACT>2018-04-04</DATE_CONCLUSION_CONTRACT>
               <NB_TENDERS_RECEIVED>2</NB_TENDERS_RECEIVED>
               <NB_TENDERS_RECEIVED_SME>1</NB_TENDERS_RECEIVED_SME>
               <AWARDED_TO_GROUP/>
               <CONTRACTOR>
                  <ADDRESS_CONTRACTOR>
                     <OFFICIALNAME>PGF „Urtica” Sp. z o.o.</OFFICIALNAME>
                     <TOWN>Wrocław</TOWN>
                     <COUNTRY VALUE="PL"/>
                     <n2016:NUTS CODE="PL514"/>
                  </ADDRESS_CONTRACTOR>
                  <NO_SME/>
               </CONTRACTOR>
               <CONTRACTOR>
                  <ADDRESS_CONTRACTOR>
                     <OFFICIALNAME>Polska Grupa Farmaceutyczna S.A.</OFFICIALNAME>
                     <TOWN>Łódź</TOWN>
                     <COUNTRY VALUE="PL"/>
                     <n2016:NUTS CODE="PL711"/>
                  </ADDRESS_CONTRACTOR>
                  <NO_SME/>
               </CONTRACTOR>
               <VAL_ESTIMATED_TOTAL CURRENCY="PLN">38224.00</VAL_ESTIMATED_TOTAL>
               <VAL_TOTAL CURRENCY="PLN">17580.24</VAL_TOTAL>
            </AWARDED_CONTRACT>
         </AWARD_CONTRACT>
         <AWARD_CONTRACT ITEM="13">
            <CONTRACT_NO>13</CONTRACT_NO>
            <LOT_NO>13</LOT_NO>
            <TITLE>
               <P>Sunitinib</P>
            </TITLE>
            <AWARDED_CONTRACT>
               <DATE_CONCLUSION_CONTRACT>2018-03-27</DATE_CONCLUSION_CONTRACT>
               <NB_TENDERS_RECEIVED>1</NB_TENDERS_RECEIVED>
               <AWARDED_TO_GROUP/>
               <CONTRACTOR>
                  <ADDRESS_CONTRACTOR>
                     <OFFICIALNAME>PGF „Urtica” Sp. z o.o.</OFFICIALNAME>
                     <TOWN>Wrocław</TOWN>
                     <COUNTRY VALUE="PL"/>
                     <n2016:NUTS CODE="PL514"/>
                  </ADDRESS_CONTRACTOR>
                  <NO_SME/>
               </CONTRACTOR>
               <CONTRACTOR>
                  <ADDRESS_CONTRACTOR>
                     <OFFICIALNAME>Polska Grupa Farmaceutyczna S.A.</OFFICIALNAME>
                     <TOWN>Łódź</TOWN>
                     <COUNTRY VALUE="PL"/>
                     <n2016:NUTS CODE="PL711"/>
                  </ADDRESS_CONTRACTOR>
                  <NO_SME/>
               </CONTRACTOR>
               <VAL_ESTIMATED_TOTAL CURRENCY="PLN">33642.00</VAL_ESTIMATED_TOTAL>
               <VAL_TOTAL CURRENCY="PLN">17653.12</VAL_TOTAL>
            </AWARDED_CONTRACT>
         </AWARD_CONTRACT>
         <AWARD_CONTRACT ITEM="14">
            <CONTRACT_NO>14</CONTRACT_NO>
            <LOT_NO>14</LOT_NO>
            <TITLE>
               <P>Temsirolimus</P>
            </TITLE>
            <AWARDED_CONTRACT>
               <DATE_CONCLUSION_CONTRACT>2018-03-27</DATE_CONCLUSION_CONTRACT>
               <NB_TENDERS_RECEIVED>1</NB_TENDERS_RECEIVED>
               <NO_AWARDED_TO_GROUP/>
               <CONTRACTOR>
                  <ADDRESS_CONTRACTOR>
                     <OFFICIALNAME>Pfizer Trading Polska Sp. z o.o..</OFFICIALNAME>
                     <TOWN>Warszawa</TOWN>
                     <COUNTRY VALUE="PL"/>
                     <n2016:NUTS CODE="PL911"/>
                  </ADDRESS_CONTRACTOR>
                  <NO_SME/>
               </CONTRACTOR>
               <VAL_ESTIMATED_TOTAL CURRENCY="PLN">20520.00</VAL_ESTIMATED_TOTAL>
               <VAL_TOTAL CURRENCY="PLN">3685.50</VAL_TOTAL>
            </AWARDED_CONTRACT>
         </AWARD_CONTRACT>
         <AWARD_CONTRACT ITEM="15">
            <CONTRACT_NO>15</CONTRACT_NO>
            <LOT_NO>15</LOT_NO>
            <TITLE>
               <P>Trastuzumab</P>
            </TITLE>
            <AWARDED_CONTRACT>
               <DATE_CONCLUSION_CONTRACT>2018-03-27</DATE_CONCLUSION_CONTRACT>
               <NB_TENDERS_RECEIVED>1</NB_TENDERS_RECEIVED>
               <NO_AWARDED_TO_GROUP/>
               <CONTRACTOR>
                  <ADDRESS_CONTRACTOR>
                     <OFFICIALNAME>Roche Polska Sp. z o.o</OFFICIALNAME>
                     <TOWN>Warszawa</TOWN>
                     <COUNTRY VALUE="PL"/>
                     <n2016:NUTS CODE="PL911"/>
                  </ADDRESS_CONTRACTOR>
                  <NO_SME/>
               </CONTRACTOR>
               <VAL_ESTIMATED_TOTAL CURRENCY="PLN">144996.00</VAL_ESTIMATED_TOTAL>
               <VAL_TOTAL CURRENCY="PLN">150498.00</VAL_TOTAL>
            </AWARDED_CONTRACT>
         </AWARD_CONTRACT>
         <AWARD_CONTRACT ITEM="16">
            <CONTRACT_NO>16</CONTRACT_NO>
            <LOT_NO>16</LOT_NO>
            <TITLE>
               <P>Bleomycin sulphate</P>
            </TITLE>
            <AWARDED_CONTRACT>
               <DATE_CONCLUSION_CONTRACT>2018-04-04</DATE_CONCLUSION_CONTRACT>
               <NB_TENDERS_RECEIVED>2</NB_TENDERS_RECEIVED>
               <NB_TENDERS_RECEIVED_SME>1</NB_TENDERS_RECEIVED_SME>
               <NO_AWARDED_TO_GROUP/>
               <CONTRACTOR>
                  <ADDRESS_CONTRACTOR>
                     <OFFICIALNAME>Asclepios S.A..</OFFICIALNAME>
                     <TOWN>Wrocław</TOWN>
                     <COUNTRY VALUE="PL"/>
                     <n2016:NUTS CODE="PL514"/>
                  </ADDRESS_CONTRACTOR>
                  <SME/>
               </CONTRACTOR>
               <VAL_ESTIMATED_TOTAL CURRENCY="PLN">4725.00</VAL_ESTIMATED_TOTAL>
               <VAL_TOTAL CURRENCY="PLN">4981.50</VAL_TOTAL>
            </AWARDED_CONTRACT>
         </AWARD_CONTRACT>
         <AWARD_CONTRACT ITEM="17">
            <CONTRACT_NO>17</CONTRACT_NO>
            <LOT_NO>17</LOT_NO>
            <TITLE>
               <P>Carbolatinum</P>
            </TITLE>
            <AWARDED_CONTRACT>
               <DATE_CONCLUSION_CONTRACT>2018-03-27</DATE_CONCLUSION_CONTRACT>
               <NB_TENDERS_RECEIVED>1</NB_TENDERS_RECEIVED>
               <NO_AWARDED_TO_GROUP/>
               <CONTRACTOR>
                  <ADDRESS_CONTRACTOR>
                     <OFFICIALNAME>Salus International Sp. z o.o.</OFFICIALNAME>
                     <TOWN>Katowice</TOWN>
                     <COUNTRY VALUE="PL"/>
                     <n2016:NUTS CODE="PL22A"/>
                  </ADDRESS_CONTRACTOR>
                  <NO_SME/>
               </CONTRACTOR>
               <VAL_ESTIMATED_TOTAL CURRENCY="PLN">52380.00</VAL_ESTIMATED_TOTAL>
               <VAL_TOTAL CURRENCY="PLN">42014.70</VAL_TOTAL>
            </AWARDED_CONTRACT>
         </AWARD_CONTRACT>
         <AWARD_CONTRACT ITEM="18">
            <CONTRACT_NO>18</CONTRACT_NO>
            <LOT_NO>18</LOT_NO>
            <TITLE>
               <P>Enzalutamide</P>
            </TITLE>
            <AWARDED_CONTRACT>
               <DATE_CONCLUSION_CONTRACT>2018-03-27</DATE_CONCLUSION_CONTRACT>
               <NB_TENDERS_RECEIVED>1</NB_TENDERS_RECEIVED>
               <NB_TENDERS_RECEIVED_SME>1</NB_TENDERS_RECEIVED_SME>
               <NO_AWARDED_TO_GROUP/>
               <CONTRACTOR>
                  <ADDRESS_CONTRACTOR>
                     <OFFICIALNAME>Astellas Pharma Sp. z o.o.</OFFICIALNAME>
                     <TOWN>Warszawa</TOWN>
                     <COUNTRY VALUE="PL"/>
                     <n2016:NUTS CODE="PL911"/>
                  </ADDRESS_CONTRACTOR>
                  <SME/>
               </CONTRACTOR>
               <VAL_ESTIMATED_TOTAL CURRENCY="PLN">45000.00</VAL_ESTIMATED_TOTAL>
               <VAL_TOTAL CURRENCY="PLN">43128.02</VAL_TOTAL>
            </AWARDED_CONTRACT>
         </AWARD_CONTRACT>
         <COMPLEMENTARY_INFO>
            <ADDRESS_REVIEW_BODY>
               <OFFICIALNAME>Prezes Krajowej Izby Odwoławczej</OFFICIALNAME>
               <ADDRESS>ul. Postępu 17A</ADDRESS>
               <TOWN>Warszawa</TOWN>
               <POSTAL_CODE>02-676</POSTAL_CODE>
               <COUNTRY VALUE="PL"/>
               <PHONE>+48 224587777</PHONE>
               <FAX>+48 224587700</FAX>
            </ADDRESS_REVIEW_BODY>
            <DATE_DISPATCH_NOTICE>2018-04-25</DATE_DISPATCH_NOTICE>
         </COMPLEMENTARY_INFO>
      </F03_2014>
   </FORM_SECTION>
</TED_EXPORT>
